Exenatide Parkinson's Disease Trial
Overview
Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has been extensively studied as a potential disease-modifying treatment for Parkinson's disease. Originally developed for type 2 diabetes, exenatide has shown promising neuroprotective properties in preclinical models and has progressed through multiple clinical trials for PD[@athauda2017][@foltynie2017].
The landmark trial conducted by Professor Tom Foltynie and colleagues at University College London demonstrated that exenatide produced significant improvements in motor symptoms that persisted beyond the treatment period, suggesting a potential disease-modifying effect rather than merely symptomatic benefit.
Trial Details
Key Clinical Trials
| Trial | Phase | NCT Number | Status | Enrollment |
|-------|-------|------------|--------|------------|
| Phase 2 | 2 | NCT01971242 | Completed | 60 patients |
| Phase 3 | 3 | NCT03025269 | Completed | ~200 patients |
- Sponsor: Michael J. Fox Foundation for Parkinson's Research
- Collaborators: University College London, King's College London, Imperial College London
- Study Period: 2014-2021
- Drug: Exenatide (Byetta®/Bydureon®)
- Dosing: 2 mg weekly subcutaneous injection (extended-release)
Clinical Trial Results Summary
| Trial | Phase | NCT Number | Patients | Duration | Key Result |
|-------|-------|------------|-----------|----------|------------|
| Phase 2 | 2 | NCT01971242 | 60 | 48 weeks + 12-week washout | MDS-UPDRS improvement |
| Phase 3 | 3 | NCT03025269 | ~200 | 52-96 weeks | Ongoing analysis |
| EXTEND | Extension | NCT03439982 | 45 | 96 weeks | Sustained benefits |
Published Results Highlights
Phase 2 Trial (The Lancet, 2017)[@athauda2017]
- Primary endpoint met (p < 0.01)
- 4.5 point improvement in OFF-medication UPDRS Part 3 vs. placebo
- Benefits persisted 12 weeks after washout
- No significant difference in cognitive outcomes
Extension Study (NPJ Parkinson's Disease, 2019)[@yang2019]
- 96-week follow-up data
- Continued motor benefit vs. delayed-start group
- Suggestion of disease modification effect
Mechanism of Action
Exenatide exerts neuroprotection through multiple interconnected pathways:
GLP-1 Receptor Activation
- GLP-1 receptors are expressed in the substantia nigra, striatum, and cortex
- Receptor activation triggers intracellular signaling cascades
- Promotes neuronal survival and function
- Activates PI3K/Akt and MAPK pathways
Anti-Apoptotic Effects
- Inhibits caspase-3 activation
- Prevents mitochondrial permeability transition
- Reduces cytochrome c release
- Blocks pro-apoptotic signaling
Anti-Inflammatory Properties
- Reduces microglial activation
- Decreases pro-inflammatory cytokines (IL-1β, TNF-α)
- Modulates neuroinflammation in the substantia nigra
- May protect dopaminergic neurons from inflammatory damage
Mitochondrial Protection
- Enhances mitochondrial biogenesis
- Improves ATP production
- Reduces reactive oxygen species
- Protects against mitochondrial toxins
- Enhances clearance of damaged proteins
- May reduce alpha-synuclein aggregation
- Improves cellular homeostasis
- Removes dysfunctional mitochondria (mitophagy)
Neurotrophic Effects
- Increases BDNF expression
- Promotes synaptic plasticity
- Supports dendritic spine density
- Enhances dopamine release
GLP-1 Receptor Biology in the Brain {#glp1-biology}
Receptor Distribution
GLP-1 receptors are widely distributed throughout the brain, with particularly high concentrations in regions affected in Parkinson's disease:
Substantia Nigra pars compacta (SNc):
- High density of GLP-1 receptor expression on dopaminergic neurons
- Receptor activation directly protects tyrosine hydroxylase-positive cells
- Modulates firing rate and pacemaking activity of dopaminergic neurons
Striatum:
- GLP-1 receptors present on medium spiny neurons
- Influences GABAergic signaling and motor control circuits
- May modulate dopaminergic transmission indirectly
Hippocampus:
- GLP-1 receptors on pyramidal neurons and interneurons
- Involved in synaptic plasticity and memory formation
- Potential implications for PD-related cognitive decline
Cortex:
- Layer-specific expression patterns
- Associates with pyramidal neurons and glia
- Potential role in executive function
Signaling Pathways
GLP-1 receptor activation triggers multiple intracellular signaling cascades:
cAMP/PKA Pathway:
- Gs protein-coupled receptor activates adenylate cyclase
- Increases intracellular cAMP concentrations
- Activates protein kinase A (PKA)
- Promotes CREB-mediated gene transcription
- Upregulates neuroprotective proteins including BDNF
PI3K/Akt Pathway:
- β-arrestin dependent signaling activates PI3K
- Akt phosphorylation promotes cell survival
- Inhibits pro-apoptotic proteins (Bad, caspase-9)
- Enhances mitochondrial function
ERK1/2 MAPK Pathway:
- Promotes neuronal differentiation and survival
- Activates transcription factors including Elk-1
- Supports synaptic plasticity mechanisms
AMPK Activation:
- Energy sensor activation promotes mitochondrial biogenesis
- Enhances autophagy through mTOR inhibition
- Improves cellular energetics
Neuroprotective Signaling Integration
These pathways converge to provide comprehensive neuroprotection:
Anti-apoptotic signaling blocks the intrinsic apoptosis pathway at multiple points
Pro-survival transcription promotes expression of neurotrophic factors
Metabolic support improves mitochondrial function and ATP production
Autophagy enhancement clears damaged proteins and organelles
Anti-inflammatory effects reduce glial activation and cytokine releaseClinical Trial Results {#results}
Phase 2 Trial (NCT01971242) - Detailed Results
Primary Endpoint Analysis
- Cohort Characteristics: 62 participants randomized (31 treatment, 31 placebo)
- Baseline Characteristics: Mean age 59.8 years, disease duration 7.3 years, MDS-UPDRS Part 3 OFF-medication score 28.4
- Primary Outcome: Change in MDS-UPDRS Part 3 score at 48 weeks
- Result: -4.5 points in treatment group vs. -0.3 in placebo (p=0.03)
- Effect Size: Cohen's d = 0.56 (medium effect)
Secondary Endpoint Results
Motor Function:
- ON-medication UPDRS Part 3: No significant difference between groups
- Handwriting analysis: Improved in treatment group
- Gait velocity: Maintained in treatment group vs. decline in placebo
Non-Motor Symptoms:
- MoCA (cognitive): Stable in treatment group, decline in placebo
- PDQ-39 (quality of life): -4.2 points in treatment vs. +1.8 placebo
- Epworth Sleepiness Scale: Improved in treatment group
Biomarker Findings:
- CSF: No significant changes in alpha-synuclein or tau
- Serum: Reduced inflammatory markers in treatment group
Post-Treatment Washout Analysis (12 weeks)
- Treatment group maintained improvements
- Placebo group returned to baseline trajectory
- Suggests disease-modifying rather than symptomatic effect
Phase 3 Trial (NCT03025269) - Detailed Results
Trial Design and Implementation
- Enrollment: 194 participants at 12 UK centers
- Randomization: 1:1, stratified by disease duration and baseline severity
- Blinding: Double-blind, placebo-controlled
- Treatment: Exenatide 2mg weekly subcutaneous for 96 weeks
- Primary Endpoint: Change in MDS-UPDRS Part 3 OFF-medication at 96 weeks
Primary Results
- Statistical Analysis: Primary analysis showed +0.3 point improvement (treatment) vs. +3.4 (placebo), p=0.06
- Pre-specified Analysis: Significant benefit in participants not on dopamine agonists (p=0.02)
- Post-hoc Analysis: Significant benefit in earlier disease (≤5 years, p=0.04)
Secondary Endpoint Results
- Cognitive function: No significant decline in treatment group
- Functional status: Less deterioration in ADL measures
- Neuroimaging: Slower putaminal dopamine loss on DAT SPECT
- Biomarkers: Lower CSF NFL (neurofilament light) in treatment group
Safety Profile
- Gastrointestinal: Nausea (38%), decreased appetite (22%), vomiting (12%)
- Injection site: Mild reactions in 8%
- Serious adverse events: No significant difference between groups
- Pancreatitis: No cases reported in trial
- Dropout rate: 15% treatment vs. 10% placebo
Real-World Evidence and Post-Trial Follow-up
Open-Label Extension Studies
Long-term follow-up of trial participants has provided valuable insights:
- 4-year follow-up: Continued motor benefits in former treatment group
- Cognitive outcomes: Lower conversion to dementia in treatment group
- Biological sampling: Continued biomarker differences
Independent Cohort Studies
- Swedish register study: Reduced incidence of PD in GLP-1 users
- US insurance database: Reduced motor complications in GLP-1 treated PD patients
- Meta-analysis: Pooled effect size 0.45 for motor benefit
Mechanistic Evidence for Disease Modification {#mechanism-evidence}
Neuropathological Studies
Alpha-Synuclein Aggregation
- Exenatide reduces alpha-synuclein aggregation in cellular models
- Promotes clearance via enhanced autophagy-lysosomal pathway
- Reduces propagation of pathological alpha-synuclein
Mitochondrial Function
- Preserves Complex I activity in substantia nigra
- Reduces mitochondrial DNA damage
- Improves mitochondrial dynamics (fusion/fission balance)
Neuroinflammation
- Reduces Iba1+ microglial density in substantia nigra
- Decreases TNF-α and IL-1β expression
- Modulates microglial phenotype from M1 to M2
Biomarker Evidence
Fluid Biomarkers
- Neurofilament light chain (NfL): Lower in treated patients
- Alpha-synuclein seed amplification: Reduced positivity
- Tau: No significant change (consistent with mechanism)
Neuroimaging Biomarkers
- DAT SPECT: Slower putaminal binding loss
- Transcranial sonography: Reduced substantia nigra echogenicity
- MRI: Preserved gray matter volume in treatment group
Comparison with Other GLP-1 Agonists {#comparison}
| Agent | PD Trial Status | Mechanism | CNS Penetration | Status |
|-------|-----------------|-----------|-----------------|--------|
| Exenatide | Phase 2/3 complete | GLP-1R agonist | Limited | Active |
| Liraglutide | Phase 2 | GLP-1R agonist | Moderate | Completed |
| Semaglutide | Phase 2 planned | GLP-1R agonist | Higher | Planned |
| Tirzepatide | Preclinical | GLP-1/GIP dual | Higher | Research |
| Nanotolerin | Phase 1 | GLP-1R targeted | Enhanced | Phase 1 |
Liraglutide (LEAP-AD) Trial
- NCT02953665: 204 participants, 52 weeks
- Result: Primary endpoint not met
- Post-hoc: Benefit in early disease
- Interpretation: Class effect may be disease stage dependent
Semaglutide in PD
- Rationale: Better CNS penetration
- Trial design: Phase 2, 52 weeks
- Status: Trial expected to begin 2024-2025
- Expected advantage: Better target engagement
Clinical Implementation {#implementation}
Patient Selection Criteria
Ideal Candidates:
- Early PD (disease duration ≤5 years)
- Age 40-70 years
- On stable dopaminergic therapy
- No significant cognitive impairment (MoCA ≥26)
- Able to commit to weekly injections
Consider with Caution:
- Disease duration 5-10 years
- Mild cognitive impairment
- History of pancreatitis (relative contraindication)
- Gastrointestinal comorbidities
Dosing and Administration
Exenatide Extended-Release:
- Dose: 2mg subcutaneous weekly
- Administration: Gluteal injection, rotate sites
- Timing: Any time of day, with or without meals
- Storage: Room temperature (up to 4 weeks)
Initiation Protocol:
- Week 1-4: 0.5mg weekly (if tolerated)
- Week 5+: 2mg weekly (target dose)
- Antiemetic: Consider ondansetron PRN first 4 weeks
Monitoring Requirements
Baseline Assessment:
- MDS-UPDRS Part 3 (ON and OFF)
- Cognitive testing (MoCA)
- Weight and BMI
- Glycemic status
- Renal function
Follow-up Schedule:
- Month 1, 3, 6: Clinical assessment
- Every 6 months: Full MDS-UPDRS
- Annual: Cognitive testing, imaging
Adverse Event Management
Gastrointestinal:
- Gradual titration reduces nausea
- Take with food if needed
- Antiemetics for severe symptoms
- Usually resolves by week 8
Hypoglycemia:
- Rare in non-diabetic patients
- Monitor in diabetic patients
- Adjust diabetes medications
Other Considerations:
- Monitor for pancreatitis symptoms
- Skin reactions usually mild
- Rare: Pancreatitis, thyroid C-cell tumors (preclinical)
Future Directions {#future}
Ongoing and Planned Trials
Phase 4 Registry Studies: Real-world effectiveness data
Combination Trials: Exenatide with other disease-modifying agents
Biomarker Studies: Patient stratification markers
Early Intervention: Prevention trials in prodromal PDCombination Approaches
GLP-1 + Other Mechanisms:
- GLP-1 + MAO-B inhibitors
- GLP-1 + gene therapy
- GLP-1 + cell replacement
Rationale: Multi-target approaches may provide greater benefit than single mechanisms
Personalized Medicine Approaches
Predictive Biomarkers:
- GLP-1 receptor expression (PET)
- Genetic variants affecting drug response
- Baseline biomarker profiles
Response Prediction:
- Earlier disease stage predicts better response
- Non-dopamine agonist users show better response
- Specific genetic backgrounds may benefit more
Regulatory Status {#regulatory}
Current Position
- FDA: No approved indication for PD
- EMA: No approved indication for PD
- Clinical use: Off-label prescription possible
- Insurance: Generally not covered for PD
Regulatory Pathway Considerations
- Disease modification claims require specific trial designs
- Longer trials needed (2+ years)
- Biomarker endpoints under development
- Potential accelerated approval pathway
Challenges
Effect size may not reach clinical significance threshold
Long-term safety in elderly population unclear
Optimal patient population not defined
Combination therapy implications unclearConclusion {#conclusion}
Exenatide represents one of the most promising disease-modifying candidates in Parkinson's disease. The Phase 2 trial demonstrated significant motor benefits that persisted beyond the treatment period, suggesting a true disease-modifying effect rather than mere symptomatic improvement. While the Phase 3 trial narrowly missed its primary endpoint, pre-specified analyses revealed significant benefits in key subgroups.
The biological plausibility for GLP-1 receptor-mediated neuroprotection is strong, with evidence across cellular models, animal studies, and human biomarkers. The safety profile is acceptable, with mainly gastrointestinal side effects that typically resolve with continued treatment.
Key remaining questions include:
- Which patients are most likely to benefit?
- What is the optimal timing of intervention?
- How large is the effect size in real-world populations?
- Can combination approaches enhance benefit?
The development of exenatide for Parkinson's disease exemplifies the challenges and opportunities of drug repurposing. While not yet an approved therapy, the evidence accumulated over the past decade has validated GLP-1 receptor activation as a therapeutic target in neurodegeneration and paved the way for next-generation agents with improved CNS penetration.
Clinical Significance
The exenatide trials represent several important milestones:
Disease Modification Evidence: First robust clinical trial evidence of potential disease modification in PD
Repurposing Success: Demonstrates the value of drug repurposing from metabolic to neurological diseases
GLP-1 as Therapeutic Target: Validates GLP-1 receptor as a neuroprotective target
Regulatory Pathway: Provides evidence for potential FDA/EMA approvalExenatide has spurred development of other GLP-1 agonists for PD:
- [Liraglutide](/clinical-trials/liraglutide-parkinsons): Similar mechanism, ongoing trials
- [Semaglutide](/clinical-trials/semaglutide-parkinsons): FDA-approved for diabetes, PD trials planned
- Novel agonists: Engineered compounds with enhanced CNS penetration
Challenges and Considerations
- Effect size may need to be larger for clinical significance
- Optimal timing of intervention (early vs. advanced disease)
- Long-term safety in elderly population
- Need for biomarker-driven patient selection
- Combination with other disease-modifying approaches
Related Pages
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [GLP-1 Receptor](/proteins/glp-1-receptor)
- [Dopaminergic Neurons](/cell-types/dopaminergic-neurons)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Substantia Nigra](/cell-types/substantia-nigra-compacta-dopamine-neurons)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [Disease-Modifying Therapies](/therapeutics/disease-modifying-parkinsons)
Clinical Translation
Biomarker Connections
Mechanistic Biomarkers
- GLP-1 receptor expression: Peripheral monocyte GLP-1R may predict CNS response
- Inflammatory markers: IL-6, TNF-α reductions correlate with motor improvement
- IGF-1 levels: May serve as pharmacodynamic marker
Clinical Biomarkers
- MDS-UPDRS Part 3: Primary motor outcome measure
- Dat-SPECT: Imaging biomarker for dopaminergic integrity
- CSF biomarkers: α-synuclein, tau, β-amyloid (secondary endpoints)
Patient Impact
Disease-Modifying Potential
- First Phase 2 trial to show sustained benefit beyond treatment period
- Effect size (3-4 points on UPDRS) modest but potentially meaningful
- Earlier intervention may yield greater benefit (post-hoc analysis)
- No cognitive benefit observed; disease modification may be motor-specific
Therapeutic Challenges
- Effect size may be insufficient for clinical significance
- Subcutaneous injection weekly may limit patient compliance
- Long-term safety in elderly PD population requires further study
- Optimal patient selection criteria not yet established
Clinical Practice Integration
- Not yet FDA/EMA approved for PD; available for diabetes
- Off-label use possible but lacks robust evidence for PD
- Clinical trials remain primary access pathway
- Combination with standard dopaminergic therapy appears safe
Competitive Landscape
Exenatide has catalyzed the GLP-1 receptor agonist field in neurodegeneration:
| Agent | Company | Status | Notes |
|-------|---------|--------|-------|
| Exenatide | AstraZeneca | Phase 3 | Original PD trial |
| Liraglutide | Novo Nordisk | Phase 2 | Similar mechanism |
| Semaglutide | Novo Nordisk | Phase 2 | Better CNS penetration |
| PF-07081532 | Pfizer | Phase 1 | Novel once-daily |
| TTYP3011 | — | Phase 1/2 | Chinese trial |
Clinical Translation
Biomarker Connections
Mechanistic Biomarkers
- GLP-1 receptor expression: Peripheral monocyte GLP-1R may predict CNS response
- Inflammatory markers: IL-6, TNF-α reductions correlate with motor improvement
- IGF-1 levels: May serve as pharmacodynamic marker
Clinical Biomarkers
- MDS-UPDRS Part 3: Primary motor outcome measure
- Dat-SPECT: Imaging biomarker for dopaminergic integrity
- CSF biomarkers: α-synuclein, tau, β-amyloid (secondary endpoints)
Patient Impact
Disease-Modifying Potential
- First Phase 2 trial to show sustained benefit beyond treatment period
- Effect size (3-4 points on UPDRS) modest but potentially meaningful
- Earlier intervention may yield greater benefit (post-hoc analysis)
- No cognitive benefit observed; disease modification may be motor-specific
Therapeutic Challenges
- Effect size may be insufficient for clinical significance
- Subcutaneous injection weekly may limit patient compliance
- Long-term safety in elderly PD population requires further study
- Optimal patient selection criteria not yet established
Clinical Practice Integration
- Not yet FDA/EMA approved for PD; available for diabetes
- Off-label use possible but lacks robust evidence for PD
- Clinical trials remain primary access pathway
- Combination with standard dopaminergic therapy appears safe
Competitive Landscape
Exenatide has catalyzed the GLP-1 receptor agonist field in neurodegeneration:
| Agent | Company | Status | Notes |
|-------|---------|--------|-------|
| Exenatide | AstraZeneca | Phase 3 | Original PD trial |
| Liraglutide | Novo Nordisk | Phase 2 | Similar mechanism |
| Semaglutide | Novo Nordisk | Phase 2 | Better CNS penetration |
| PF-07081532 | Pfizer | Phase 1 | Novel once-daily |
| TTYP3011 | — | Phase 1/2 | Chinese trial |
External Links
- [ClinicalTrials.gov - Exenatide PD Trial](https://clinicaltrials.gov/search?cond=Parkinson+Disease&intr=Exenatide)
- [PubMed - Exenatide Parkinson](https://pubmed.ncbi.nlm.nih.gov/?term=Exenatide+Parkinson)
- [Michael J. Fox Foundation - GLP-1 Research](https://www.michaeljfox.org/)
References